<DOC>
	<DOCNO>NCT01989936</DOCNO>
	<brief_summary>To determine tolerability efficacy eletriptan patient discontinue oral sumatriptan due lack efficacy intolerable adverse event ( AEs ) previous clinical treatment ( control trial ) .</brief_summary>
	<brief_title>Eletriptan Treatment Migraine Patients With Previous Poor Response Tolerance Oral Sumatriptan</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Eletriptan</mesh_term>
	<criteria>Male female subject age â‰¥ 18 year meet International Headache Society ( IHS ) diagnostic criterion migraine , without aura , could reasonably expect suffer least one acute attack migraine every 6 week . Subjects require discontinue therapy oral sumatriptan least 2 week , longer 2 year , prior screen visit . Female subject require adequately protected pregnancy . pregnancy breastfeeding , know coronary artery disease , significant arrhythmia , heart failure , significant ECG abnormality , uncontrolled hypertension . Any significant systemic , organ , neurological , endocrine , metabolic , psychological disorder report patient discover physical examination Subjects consider atypical migraine frequent attack , prolong aura migraine consider atypical . Subjects , course trial , require treatment sumatriptan 5HT1B/1D agonist addition study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>